General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Ardelyx(SIGNIFICANT), Glaxo Smithkline(SIGNIFICANT), ReCor(SIGNIFICANT), Brainstorm Cell(NONE), i20(SIGNIFICANT), Alnylam(SIGNIFICANT), Medscape(MODEST) RESEARCH/RESEARCH GRANTS: Medtronic(SIGNIFICANT), CSL Behring(SIGNIFICANT), AbbVie, Inc.(SIGNIFICANT), Astra Zeneca(SIGNIFICANT), Esperion(SIGNIFICANT), Novartis(SIGNIFICANT)

View Full Disclosure